ClinicalTrials.gg
CompletedNCT00918580Updated Apr 21, 2014Results posted

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease

A Phase 3 interventional study of 13-valent Pneumoccocal Conjugate Vaccine in Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 19 sites in 7 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-04-21.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Non-randomized
Ages
6 Years to 17 Years
Sex
All
01

Study summary

This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine. The study will measure the amount of antibodies (the proteins that fight off germs) produced by children with Sickle Cell Disease after they have been given the 13-valent pneumococcal vaccine between 6 and less than 18 years of age. They will be given the vaccination twice, each vaccination separated by approximately 6 months.

02

Conditions studied

  • Pneumococcal Conjugate Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject between the ages of >=6 to \<18 years.
  • Diagnosis of SCD
  • 23vPS vaccination at least 6 months prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with pneumococcal conjugate vaccine.
  • Previous reaction to any vaccine or vaccine-related component or to vaccination with pneumococcal conjugate vaccine.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    1

    Biological: 13-valent Pneumoccocal Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 1 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 1 and after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with a determinate IgG antibody concentration for the given serotype at both 1 Month After 13vPnC Dose 1 and 1 Month After 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.

    Time frame: 1 Month After 13vPnC Dose 1, 1 Month After 13vPnC Dose 2

Secondary outcomes

  1. Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Participants may be represented in more than 1 category.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1

  2. Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 2 to 1 Month After 13vPnC Dose 2

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 2 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.

    Time frame: Before 13vPnC Dose 2, 1 month after 13vPnC Dose 2

  3. Ratio of Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 13vPnC Dose 1 to 13vPnC Dose 2

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were computed using the logarithmically transformed assay results for Dose 1 (after Dose 1/before Dose 1) and for Dose 2 (after Dose 2/before Dose 2). CI for the ratio of GMFR (Dose 2/Dose 1) were back transformations of a CI based on the Student t distribution for the mean logarithm of the measures (Dose 2 - Dose 1). Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for given serotype at before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2

  4. Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at specified time point. Participants may be represented in more than 1 category.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2

  5. Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Year After 13vPnC Dose 2

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate IgG antibody concentration for the given serotype. Participants may be represented in more than 1 category.

    Time frame: 1 year after 13vPnC Dose 2

  6. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)

    Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate OPA antibody titer for the given serotype at specified time point. Participants may be represented in more than 1 category.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2

  7. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Year After 13vPnC Dose 2

    Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate OPA antibody titer for the given serotype. Participants may be represented in more than 1 category.

    Time frame: 1 year after 13vPnC Dose 2

Other outcomes

  1. Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 1

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (less than \<2.5 centimeters \[cm\] for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than or equal to \[\>=\] 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here "Number of participants analyzed" signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after 13vPnC Dose 1

  2. Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 2

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (\<2.5 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>=12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after 13vPnC Dose 2

  3. Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 1

    Specific systemic events (fever \>=38 degrees Celsius\[C\], vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, use of antipyretic medications) were prompted for each day and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe(required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours);Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after 13vPnC Dose 1

  4. Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 2

    Specific systemic events (fever \>=38 degrees C, vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, and use of antipyretic medications) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours); Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after 13vPnC Dose 2

07

Results

Posted Apr 21, 2014

Participant flow

Up to 6-month Follow-up(FU)
Participant flow — Up to 6-month Follow-up(FU)
Milestone13vPnC
Started158
Vaccinated dose 1158
Vaccinated dose 2146
Completed147
Not completed11
Withdrew: Adverse event1
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject2
Withdrew: Parent/legal guardian request2
Withdrew: Failed to return1
After 6-month FU to 1-year FU
Participant flow — After 6-month FU to 1-year FU
Milestone13vPnC
Started147
Continued after 6-month fu89
Completed87
Not completed60
Withdrew: Did not continue after 6-month fu58
Withdrew: Failed to return2

Outcome measures

PrimaryGeometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 1 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 1 and after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with a determinate IgG antibody concentration for the given serotype at both 1 Month After 13vPnC Dose 1 and 1 Month After 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.

Time frame:
1 Month After 13vPnC Dose 1, 1 Month After 13vPnC Dose 2
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2
fold rise13vPnC
Serotype 4 (N = 137)0.75 (0.66 to 0.84)
Serotype 6B (N = 136)0.89 (0.78 to 1.02)
Serotype 9V (N = 136)0.82 (0.75 to 0.91)
Serotype 14 (N = 137)0.75 (0.67 to 0.85)
Serotype 18C (N = 137)0.70 (0.62 to 0.80)
Serotype 19F (N = 136)1.05 (0.91 to 1.20)
Serotype 23F (N = 135)0.91 (0.77 to 1.08)
Serotype 1 (N = 137)0.88 (0.77 to 0.99)
Serotype 3 (N = 134)0.82 (0.75 to 0.90)
Serotype 5 (N = 136)0.90 (0.82 to 0.98)
Serotype 6A (N = 136)0.95 (0.82 to 1.10)
Serotype 7F (N = 137)0.75 (0.67 to 0.85)
Serotype 19A (N = 137)0.83 (0.74 to 0.93)
SecondaryGeometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 1 and 1 month after 13vPnC Dose 1 blood draws. Participants may be represented in more than 1 category.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1
fold rise13vPnC
Serotype 4 (N = 136)6.91 (5.27 to 9.06)
Serotype 6B (N = 137)4.72 (3.80 to 5.85)
Serotype 9V (N = 138)3.10 (2.60 to 3.70)
Serotype 14 (N = 138)5.50 (4.05 to 7.46)
Serotype 18C (N = 137)5.58 (4.47 to 6.97)
Serotype 19F (N = 134)4.76 (3.77 to 6.03)
Serotype 23F (N = 137)6.58 (5.12 to 8.46)
Serotype 1 (N = 129)3.60 (2.90 to 4.46)
Serotype 3 (N = 133)2.03 (1.78 to 2.31)
Serotype 5 (N = 138)1.74 (1.56 to 1.94)
Serotype 6A (N = 132)4.10 (3.32 to 5.05)
Serotype 7F (N = 137)4.38 (3.62 to 5.30)
Serotype 19A (N = 138)3.28 (2.73 to 3.96)
SecondaryGeometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 2 to 1 Month After 13vPnC Dose 2

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 2 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at both the before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.

Time frame:
Before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From Before 13vPnC Dose 2 to 1 Month After 13vPnC Dose 2
fold rise13vPnC
Serotype 4 (N = 137)1.86 (1.69 to 2.04)
Serotype 6B (N = 137)1.80 (1.60 to 2.03)
Serotype 9V (N = 136)1.48 (1.37 to 1.59)
Serotype 14 (N = 137)1.24 (1.15 to 1.35)
Serotype 18C (N = 137)1.47 (1.34 to 1.62)
Serotype 19F (N = 135)2.08 (1.85 to 2.34)
Serotype 23F (N = 135)2.04 (1.75 to 2.37)
Serotype 1 (N = 136)1.73 (1.57 to 1.92)
Serotype 3 (N = 133)1.36 (1.25 to 1.47)
Serotype 5 (N = 135)1.30 (1.22 to 1.39)
Serotype 6A (N = 133)1.80 (1.60 to 2.02)
Serotype 7F (N = 137)1.75 (1.61 to 1.90)
Serotype 19A (N = 137)1.48 (1.36 to 1.61)
SecondaryRatio of Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 13vPnC Dose 1 to 13vPnC Dose 2

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were computed using the logarithmically transformed assay results for Dose 1 (after Dose 1/before Dose 1) and for Dose 2 (after Dose 2/before Dose 2). CI for the ratio of GMFR (Dose 2/Dose 1) were back transformations of a CI based on the Student t distribution for the mean logarithm of the measures (Dose 2 - Dose 1). Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for given serotype at before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2 and 1 month after 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Reported as:
Geometric mean · ratio of GMFR
Ratio of Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 13vPnC Dose 1 to 13vPnC Dose 2
ratio of GMFR13vPnC
Serotype 4 (N = 135)0.26 (0.20 to 0.35)
Serotype 6B (N = 136)0.38 (0.29 to 0.49)
Serotype 9V (N = 136)0.49 (0.41 to 0.59)
Serotype 14 (N = 137)0.22 (0.16 to 0.31)
Serotype 18C (N = 136)0.26 (0.21 to 0.34)
Serotype 19F (N = 132)0.44 (0.34 to 0.57)
Serotype 23F (N = 135)0.32 (0.24 to 0.43)
Serotype 1 (N = 127)0.47 (0.37 to 0.59)
Serotype 3 (N = 130)0.66 (0.58 to 0.75)
Serotype 5 (N = 135)0.75 (0.66 to 0.85)
Serotype 6A (N = 127)0.45 (0.35 to 0.58)
Serotype 7F (N = 136)0.39 (0.32 to 0.49)
Serotype 19A (N = 137)0.45 (0.36 to 0.55)
SecondaryGeometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate IgG antibody concentration for the given serotype at specified time point. Participants may be represented in more than 1 category.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody
microgram per milliliter (mcg/mL)13vPnC
Before 13vPnC Dose 1: Serotype 4 (N = 136)1.01 (0.80 to 1.27)
Before 13vPnC Dose 1: Serotype 6B (N = 138)5.79 (4.89 to 6.87)
Before 13vPnC Dose 1: Serotype 9V (N = 138)3.01 (2.56 to 3.53)
Before 13vPnC Dose 1: Serotype 14 (N = 138)6.30 (4.78 to 8.30)
Before 13vPnC Dose 1: Serotype 18C (N = 137)1.40 (1.14 to 1.73)
Before 13vPnC Dose 1: Serotype 19F (N = 134)4.46 (3.60 to 5.53)
Before 13vPnC Dose 1: Serotype 23F (N = 138)2.80 (2.38 to 3.30)
Before 13vPnC Dose 1: Serotype 1 (N = 129)1.57 (1.26 to 1.95)
Before 13vPnC Dose 1: Serotype 3 (N = 133)1.02 (0.83 to 1.25)
Before 13vPnC Dose 1: Serotype 5 (N = 138)4.14 (3.58 to 4.78)
Before 13vPnC Dose 1: Serotype 6A (N = 132)4.62 (3.91 to 5.46)
Before 13vPnC Dose 1: Serotype 7F (N = 137)2.16 (1.80 to 2.59)
Before 13vPnC Dose 1: Serotype 19A (N = 138)8.16 (7.03 to 9.48)
1 Month After 13vPnC Dose 1: Serotype 4 (N = 138)6.85 (5.55 to 8.44)
1 Month After 13vPnC Dose 1: Serotype 6B (N= 137)27.25 (22.09 to 33.61)
1 Month After 13vPnC Dose 1: Serotype 9V (N= 138)9.31 (7.83 to 11.07)
1 Month After 13vPnC Dose 1: Serotype 14 (N = 138)34.63 (27.77 to 43.18)
1 Month After 13vPnC Dose 1: Serotype 18C (N= 138)7.83 (6.42 to 9.54)
1 Month After 13vPnC Dose 1: Serotype 19F (N= 138)20.40 (16.03 to 25.95)
1 Month After 13vPnC Dose 1: Serotype 23F (N= 137)18.25 (14.52 to 22.95)
1 Month After 13vPnC Dose 1: Serotype 1 (N = 138)5.24 (4.30 to 6.39)
1 Month After 13vPnC Dose 1: Serotype 3 (N = 138)2.04 (1.76 to 2.38)
1 Month After 13vPnC Dose 1: Serotype 5 (N = 138)7.19 (6.19 to 8.35)
1 Month After 13vPnC Dose 1: Serotype 6A (N = 138)17.61 (14.16 to 21.91)
1 Month After 13vPnC Dose 1: Serotype 7F (N = 138)9.46 (8.17 to 10.94)
1 Month After 13vPnC Dose 1: Serotype 19A (N= 138)26.82 (22.16 to 32.46)
Before 13vPnC Dose 2: Serotype 4 (N = 138)2.77 (2.29 to 3.35)
Before 13vPnC Dose 2: Serotype 6B (N = 138)13.67 (11.23 to 16.63)
Before 13vPnC Dose 2: Serotype 9V (N = 138)5.19 (4.41 to 6.09)
Before 13vPnC Dose 2: Serotype 14 (N = 138)21.07 (17.29 to 25.67)
Before 13vPnC Dose 2: Serotype 18C (N = 138)3.73 (3.10 to 4.49)
Before 13vPnC Dose 2: Serotype 19F (N = 137)10.34 (8.32 to 12.85)
Before 13vPnC Dose 2: Serotype 23F (N = 137)8.07 (6.63 to 9.83)
Before 13vPnC Dose 2: Serotype 1 (N = 137)2.65 (2.21 to 3.19)
Before 13vPnC Dose 2: Serotype 3 (N = 135)1.27 (1.06 to 1.52)
Before 13vPnC Dose 2: Serotype 5 (N = 137)4.91 (4.26 to 5.66)
Before 13vPnC Dose 2: Serotype 6A (N = 135)9.05 (7.48 to 10.95)
Before 13vPnC Dose 2: Serotype 7F (N = 138)4.09 (3.52 to 4.74)
Before 13vPnC Dose 2: Serotype 19A (N = 138)15.13 (12.73 to 17.98)
1 Month After 13vPnC Dose 2: Serotype 4 (N = 137)5.09 (4.28 to 6.04)
1 Month After 13vPnC Dose 2: Serotype 6B (N= 137)24.52 (20.48 to 29.35)
1 Month After 13vPnC Dose 2: Serotype 9V (N= 136)7.46 (6.46 to 8.61)
1 Month After 13vPnC Dose 2: Serotype 14 (N = 137)26.19 (22.11 to 31.03)
1 Month After 13vPnC Dose 2: Serotype 18C (N= 137)5.44 (4.64 to 6.38)
1 Month After 13vPnC Dose 2: Serotype 19F (N= 136)20.56 (17.15 to 24.63)
1 Month After 13vPnC Dose 2: Serotype 23F (N= 135)16.18 (13.27 to 19.73)
1 Month After 13vPnC Dose 2: Serotype 1 (N = 137)4.51 (3.82 to 5.32)
1 Month After 13vPnC Dose 2: Serotype 3 (N = 134)1.67 (1.42 to 1.97)
1 Month After 13vPnC Dose 2: Serotype 5 (N = 136)6.33 (5.58 to 7.17)
1 Month After 13vPnC Dose 2: Serotype 6A (N = 136)16.37 (13.65 to 19.64)
1 Month After 13vPnC Dose 2: Serotype 7F (N = 137)7.06 (6.20 to 8.04)
1 Month After 13vPnC Dose 2: Serotype 19A (N= 137)22.19 (18.94 to 25.99)
SecondaryGeometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Year After 13vPnC Dose 2

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for the specified blood draw. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate IgG antibody concentration for the given serotype. Participants may be represented in more than 1 category.

Time frame:
1 year after 13vPnC Dose 2
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Year After 13vPnC Dose 2
mcg/mL13vPnC
Serotype 4 (N = 81)1.94 (1.51 to 2.48)
Serotype 6B (N = 81)11.77 (9.43 to 14.71)
Serotype 9V (N = 81)4.50 (3.61 to 5.62)
Serotype 14 (N = 81)15.89 (12.47 to 20.26)
Serotype 18C (N = 81)2.64 (2.03 to 3.42)
Serotype 19F (N = 81)9.87 (7.50 to 13.00)
Serotype 23F (N = 81)7.70 (6.15 to 9.63)
Serotype 1 (N = 79)2.12 (1.65 to 2.71)
Serotype 3 (N = 67)1.01 (0.77 to 1.33)
Serotype 5 (N = 81)4.38 (3.58 to 5.37)
Serotype 6A (N = 81)7.94 (6.45 to 9.77)
Serotype 7F (N = 81)3.47 (2.84 to 4.25)
Serotype 19A (N = 81)13.30 (10.62 to 16.65)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)

Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with determinate OPA antibody titer for the given serotype at specified time point. Participants may be represented in more than 1 category.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1, before 13vPnC Dose 2, 1 month after 13vPnC Dose 2
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)
titer13vPnC
Before 13vPnC Dose 1: Serotype 4 (N = 105)215 (129.6 to 357.2)
Before 13vPnC Dose 1: Serotype 6B (N = 105)626 (377.5 to 1037.4)
Before 13vPnC Dose 1: Serotype 9V (N = 109)234 (137.6 to 398.7)
Before 13vPnC Dose 1: Serotype 14 (N = 115)628 (425.8 to 925.7)
Before 13vPnC Dose 1: Serotype 18C (N = 95)426 (235.7 to 771.4)
Before 13vPnC Dose 1: Serotype 19F (N = 96)94 (55.0 to 160.7)
Before 13vPnC Dose 1: Serotype 23F (N = 106)34 (21.5 to 54.8)
Before 13vPnC Dose 1: Serotype 1 (N = 131)7 (5.7 to 8.8)
Before 13vPnC Dose 1: Serotype 3 (N = 107)13 (10.1 to 17.5)
Before 13vPnC Dose 1: Serotype 5 (N = 131)10 (7.8 to 13.9)
Before 13vPnC Dose 1: Serotype 6A (N = 116)246 (149.0 to 404.8)
Before 13vPnC Dose 1: Serotype 7F (N = 120)344 (220.5 to 537.9)
Before 13vPnC Dose 1: Serotype 19A (N = 127)137 (100.0 to 187.4)
1 Month After 13vPnC Dose 1: Serotype 4 (N = 108)2670 (2128.1 to 3351.1)
1 Month After 13vPnC Dose 1: Serotype 6B (N= 116)7535 (6320.5 to 8983.5)
1 Month After 13vPnC Dose 1: Serotype 9V (N= 103)2312 (1684.0 to 3172.8)
1 Month After 13vPnC Dose 1: Serotype 14 (N = 117)2288 (1906.6 to 2745.0)
1 Month After 13vPnC Dose 1: Serotype 18C (N= 103)4326 (3250.3 to 5756.8)
1 Month After 13vPnC Dose 1: Serotype 19F (N = 89)1429 (1043.5 to 1957.3)
1 Month After 13vPnC Dose 1: Serotype 23F (N= 106)1607 (1227.4 to 2102.7)
1 Month After 13vPnC Dose 1: Serotype 1 (N = 123)56 (41.0 to 77.4)
1 Month After 13vPnC Dose 1: Serotype 3 (N = 112)115 (93.0 to 142.1)
1 Month After 13vPnC Dose 1: Serotype 5 (N = 121)277 (198.4 to 385.8)
1 Month After 13vPnC Dose 1: Serotype 6A (N = 117)7845 (6581.6 to 9349.9)
1 Month After 13vPnC Dose 1: Serotype 7F (N = 123)3348 (2881.9 to 3888.5)
1 Month After 13vPnC Dose 1: Serotype 19A (N =118)1449 (1164.2 to 1804.3)
Before 13vPnC Dose 2: Serotype 4 (N = 104)1331 (1013.9 to 1748.1)
Before 13vPnC Dose 2: Serotype 6B (N = 108)4174 (3513.0 to 4958.3)
Before 13vPnC Dose 2: Serotype 9V (N = 99)1445 (1051.7 to 1985.5)
Before 13vPnC Dose 2: Serotype 14 (N = 106)1652 (1347.8 to 2024.1)
Before 13vPnC Dose 2: Serotype 18C (N = 101)1928 (1281.1 to 2901.0)
Before 13vPnC Dose 2: Serotype 19F (N = 92)516 (338.8 to 785.5)
Before 13vPnC Dose 2: Serotype 23F (N = 94)897 (619.0 to 1300.4)
Before 13vPnC Dose 2: Serotype 1 (N = 107)23 (17.1 to 32.3)
Before 13vPnC Dose 2: Serotype 3 (N = 120)56 (45.5 to 69.9)
Before 13vPnC Dose 2: Serotype 5 (N = 107)98 (69.2 to 140.2)
Before 13vPnC Dose 2: Serotype 6A (N = 113)4005 (3350.6 to 4786.3)
Before 13vPnC Dose 2: Serotype 7F (N = 112)1791 (1427.0 to 2248.6)
Before 13vPnC Dose 2: Serotype 19A (N = 108)677 (544.4 to 843.1)
1 Month After 13vPnC Dose 2: Serotype 4 (N = 105)3051 (2536.7 to 3670.3)
1 Month After 13vPnC Dose 2: Serotype 6B (N= 107)7601 (6392.6 to 9038.6)
1 Month After 13vPnC Dose 2: Serotype 9V (N = 96)3467 (2784.0 to 4317.6)
1 Month After 13vPnC Dose 2: Serotype 14 (N = 110)2081 (1770.5 to 2446.0)
1 Month After 13vPnC Dose 2: Serotype 18C (N= 103)5271 (4267.8 to 6510.1)
1 Month After 13vPnC Dose 2: Serotype 19F (N = 89)1507 (1139.9 to 1992.2)
1 Month After 13vPnC Dose 2: Serotype 23F (N= 105)2330 (1880.4 to 2887.0)
1 Month After 13vPnC Dose 2: Serotype 1 (N = 106)78 (59.5 to 101.2)
1 Month After 13vPnC Dose 2: Serotype 3 (N = 109)105 (87.2 to 127.2)
1 Month After 13vPnC Dose 2: Serotype 5 (N = 118)273 (213.9 to 349.2)
1 Month After 13vPnC Dose 2: Serotype 6A (N = 111)7633 (6439.6 to 9048.6)
1 Month After 13vPnC Dose 2: Serotype 7F (N = 114)3723 (3276.2 to 4230.1)
1 Month After 13vPnC Dose 2: Serotype 19A (N= 115)1314 (1084.4 to 1592.6)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Year After 13vPnC Dose 2

Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMT and corresponding 2-sided 95% CIs were evaluated. CIs for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here number of participants analyzed signifies the evaluable immunogenicity population at 1-year follow-up and "N" signifies participants with determinate OPA antibody titer for the given serotype. Participants may be represented in more than 1 category.

Time frame:
1 year after 13vPnC Dose 2
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Year After 13vPnC Dose 2
titer13vPnC
Serotype 4 (N = 58)1107 (764.4 to 1602.2)
Serotype 6B (N = 59)3412 (2746.4 to 4238.7)
Serotype 9V (N = 66)1690 (1157.8 to 2465.5)
Serotype 14 (N = 64)1595 (1281.6 to 1984.9)
Serotype 18C (N = 59)1604 (1107.2 to 2324.2)
Serotype 19F (N = 55)620 (376.6 to 1020.4)
Serotype 23F (N = 58)924 (654.2 to 1306.1)
Serotype 1 (N = 73)25 (17.5 to 35.4)
Serotype 3 (N = 72)31 (22.6 to 42.6)
Serotype 5 (N = 71)102 (70.5 to 148.0)
Serotype 6A (N = 72)2485 (1921.2 to 3214.3)
Serotype 7F (N = 73)2166 (1861.4 to 2519.3)
Serotype 19A (N = 73)589 (449.4 to 771.1)
Other pre-specifiedPercentage of Participants With Prespecified Local Reactions: 13vPnC Dose 1

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (less than \<2.5 centimeters \[cm\] for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than or equal to \[\>=\] 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here "Number of participants analyzed" signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after 13vPnC Dose 1
Reported as:
Number · percentage of participants
Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 1
percentage of participants13vPnC
Pain: Any (N = 144)89.6
Pain: Mild (N = 132)81.8
Pain: Moderate (N = 113)56.6
Pain: Severe (N = 90)11.1
Redness: Any (N = 93)23.7
Redness: Mild (N = 93)20.4
Redness: Moderate (N = 90)8.9
Redness: Severe (N = 87)1.1
Swelling: Any (N = 108)49.1
Swelling: Mild (N = 101)37.6
Swelling: Moderate (N = 100)26.0
Swelling: Severe (N = 87)1.1
Other pre-specifiedPercentage of Participants With Prespecified Local Reactions: 13vPnC Dose 2

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as: Any (redness present or swelling present); Mild (\<2.5 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>=12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>=12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>=12 years). Pain was scaled as: Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified local reaction. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after 13vPnC Dose 2
Reported as:
Number · percentage of participants
Percentage of Participants With Prespecified Local Reactions: 13vPnC Dose 2
percentage of participants13vPnC
Pain: Any (N = 111)85.6
Pain: Mild (N = 103)77.7
Pain: Moderate (N = 82)53.7
Pain: Severe (N = 69)15.9
Redness: Any (N = 67)26.9
Redness: Mild (N = 66)15.2
Redness: Moderate (N = 64)14.1
Redness: Severe (N = 63)0.0
Swelling: Any (N = 84)53.6
Swelling: Mild (N = 77)37.7
Swelling: Moderate (N = 73)35.6
Swelling: Severe (N = 63)0.0
Other pre-specifiedPercentage of Participants With Prespecified Systemic Events: 13vPnC Dose 1

Specific systemic events (fever \>=38 degrees Celsius\[C\], vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, use of antipyretic medications) were prompted for each day and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe(required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours);Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 1 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after 13vPnC Dose 1
Reported as:
Number · percentage of participants
Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 1
percentage of participants13vPnC
Fever: >=38, =<38.4 degrees C (N = 81)13.6
Fever: >38.4, =<38.9 degrees C (N = 82)7.3
Fever: >38.9, =<40 degrees C (N = 79)3.8
Fever: >40 degrees C (N = 79)1.3
Vomiting: Any (N = 91)15.4
Vomiting: Mild (N = 89)11.2
Vomiting: Moderate (N = 90)6.7
Vomiting: Severe (N = 87)0.0
Diarrhea: Any (N = 90)13.3
Diarrhea: Mild (N = 87)6.9
Diarrhea: Moderate (N = 90)6.7
Diarrhea: Severe (N = 87)2.3
Headache: Any (N = 110)53.6
Headache: Mild (N = 105)42.9
Headache: Moderate (N = 101)34.7
Headache: Severe (N = 92)12.0
Fatigue: Any (N = 118)66.1
Fatigue: Mild (N = 108)48.1
Fatigue: Moderate (N = 104)44.2
Fatigue: Severe (N = 90)14.4
Muscle Pain: Any (N = 127)74.8
Muscle Pain: Mild (N = 114)58.8
Muscle Pain: Moderate (N = 108)47.2
Muscle Pain: Severe (N = 89)10.1
Joint Pain: Any (N = 103)39.8
Joint Pain: Mild (N = 98)23.5
Joint Pain: Moderate (N = 94)23.4
Joint Pain: Severe (N = 89)4.5
Use of Antipyretic Medications (N = 110)58.2
Other pre-specifiedPercentage of Participants With Prespecified Systemic Events: 13vPnC Dose 2

Specific systemic events (fever \>=38 degrees C, vomiting, diarrhea, headache, fatigue, muscle pain, joint pain, and use of antipyretic medications) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any(symptom present); Mild(did not interfere with activity); Moderate(some interference); Severe(prevented routine daily activity). Vomiting was scaled as: Any(vomiting present); Mild(1-2 times in 24 hours); Moderate(\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any(diarrhea present); Mild(2-3 loose stools in 24 hours); Moderate(4-5 loose stools 24 hours); Severe(\>=6 loose stools in 24 hours). Here number of participants analyzed signifies the safety population for Dose 2 and "N" signifies those participants who reported "Yes" for at least 1 day or "No" for all days for specified systemic event. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after 13vPnC Dose 2
Reported as:
Number · percentage of participants
Percentage of Participants With Prespecified Systemic Events: 13vPnC Dose 2
percentage of participants13vPnC
Fever: >=38, =<38.4 degrees C (N = 63)9.5
Fever: >38.4, =<38.9 degrees C (N = 59)6.8
Fever: >38.9, =<40 degrees C (N = 63)6.3
Fever: >40 degrees C (N = 60)1.7
Vomiting: Any (N = 67)13.4
Vomiting: Mild (N = 65)9.2
Vomiting: Moderate (N = 64)4.7
Vomiting: Severe (N = 64)1.6
Diarrhea: Any (N = 68)25.0
Diarrhea: Mild (N = 68)19.1
Diarrhea: Moderate (N = 66)12.1
Diarrhea: Severe (N = 63)3.2
Headache: Any (N = 86)59.3
Headache: Mild (N = 74)41.9
Headache: Moderate (N = 76)36.8
Headache: Severe (N = 66)10.6
Fatigue: Any (N = 96)62.5
Fatigue: Mild (N = 84)48.8
Fatigue: Moderate (N = 83)41.0
Fatigue: Severe (N = 67)13.4
Muscle Pain: Any (N = 98)75.5
Muscle Pain: Mild (N = 87)60.9
Muscle Pain: Moderate (N = 84)45.2
Muscle Pain: Severe (N = 67)16.4
Joint Pain: Any (N = 78)44.9
Joint Pain: Mild (N = 72)34.7
Joint Pain: Moderate (N = 70)21.4
Joint Pain: Severe (N = 65)6.2
Use of Antipyretic Medications (N = 78)43.6

Adverse events

Collected over SAEs: 13vPnC Dose 1 through 1-year follow-up after 13vPnC Dose 2. AEs: 13vPnC Dose 1; 13vPnC Dose 2; 6-month follow-up after 13vPnC Dose 2; 1-year follow-up after 13vPnC Dose 2. Local reactions/systemic events: within 7 days after 13vPnC Dose 1 and Dose 2. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Dose 1—40/158 (25.3%)133/158 (84.2%)
13vPnC Dose 2—11/140 (7.9%)100/140 (71.4%)
6-Month Follow-up—28/147 (19%)1/147 (0.7%)
1-Year Follow-up—16/87 (18.4%)1/87 (1.1%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
Event13vPnC Dose 113vPnC Dose 26-Month Follow-up1-Year Follow-up
Sickle cell anaemia with crisisCongenital, familial and genetic disorders22/1585/14017/14711/87
PneumoniaInfections and infestations1/1580/1402/1474/87
PyrexiaGeneral disorders5/1580/1402/1473/87
Acute chest syndromeRespiratory, thoracic and mediastinal disorders3/1580/1402/1471/87
Vascular occlusionVascular disorders3/1582/1400/1470/87
Pain in extremityMusculoskeletal and connective tissue disorders1/1582/1400/1470/87
PregnancyPregnancy, puerperium and perinatal conditions0/1582/1400/1470/87
PainGeneral disorders1/1580/1402/1471/87
Upper respiratory tract infectionInfections and infestations2/1580/1400/1470/87
Back painMusculoskeletal and connective tissue disorders2/1580/1401/1470/87
Most frequent other events
Showing 10 of 96
Most frequent other events
Event13vPnC Dose 113vPnC Dose 26-Month Follow-up1-Year Follow-up
Pain (Any)Skin and subcutaneous tissue disorders129/14495/111——
Pain (Mild)Skin and subcutaneous tissue disorders108/13280/103——
Muscle pain (Any)General disorders95/12774/98——
Fatigue (Any)General disorders78/11860/96——
Muscle pain (Mild)General disorders67/11453/87——
Headache (Any)General disorders59/11051/86——
Pain (Moderate)Skin and subcutaneous tissue disorders64/11344/82——
Swelling (Any)Skin and subcutaneous tissue disorders53/10845/84——
Fatigue (Mild)General disorders52/10841/84——
Muscle pain (Moderate)General disorders51/10838/84——

Baseline characteristics

All-available immunogenicity (AAI) population included all participants who had at least 1 valid and determinate pneumococcal assay result for the planned analysis.

Age, Continuous
Age, Continuous(years)13vPnC
Mean13.3 ± 3.08
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC
Female76
Male82
08

Study locations

19 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35233, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40202-3830, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40202, United States
  • Pfizer Investigational Site
    Bronx, New York 10467, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Cairo, 11361, Egypt
  • Pfizer Investigational Site
    Cairo, 11511, Egypt
  • Pfizer Investigational Site
    Paris, 75015, France
  • Pfizer Investigational Site
    Orbassano (TO), 10043, Italy
  • Pfizer Investigational Site
    Roma, 00165, Italy
  • Pfizer Investigational Site
    Beirut, 2833-7401, Lebanon
  • Pfizer Investigational Site
    Beirut, Lebanon
  • Pfizer Investigational Site
    Riyadh, Saudi, Saudi Arabia
  • Pfizer Investigational Site
    Manchester, Cheshire M27 4HA, United Kingdom
  • Pfizer Investigational Site
    London, E1 1BB, United Kingdom
  • Pfizer Investigational Site
    London, SE1 7RH, United Kingdom
  • Pfizer Investigational Site
    London, SE1 9RT, United Kingdom
  • Pfizer Investigational Site
    London, SE5 9RS, United Kingdom
  • Pfizer Investigational Site
    London, SW17 0RE, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2009
First posted
Jun 11, 2009
Start
Nov 2009
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Apr 21, 2014
Last update
Apr 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00918580
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 11, 2009
Start date
Nov 2009
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Apr 21, 2014
Last update
Apr 21, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion